Glutathione is a tripeptide — composed of three amino acids: L-glutamate, L-cysteine, and L-glycine — that the body synthesizes and uses as its primary intracellular antioxidant. Unlike most compounds sold in the research peptide market, it is not synthetic; the liver produces it continuously, and nearly every cell in the body maintains its own supply. What makes glutathione relevant to aging research is a consistent pattern: intracellular levels measurably decline with age, with chronic illness, and under oxidative stress — and that decline correlates with worsening health outcomes across a range of conditions.
- Oxidative stress and aging Researchers have examined glutathione deficiency as a driver of aging hallmarks — studies suggest that correcting this deficiency via supplementation or precursors (GlyNAC) improves mitochondrial function, reduces oxidative damage, and reverses multiple markers of biological aging in older adults. [1] [2]
- Metabolic health and type 2 diabetes Elevated blood glucose depletes glutathione through oxidative stress; studies in type 2 diabetic patients have found that six months of oral glutathione supplementation significantly increased blood glutathione levels, reduced 8-OHdG (a DNA oxidative damage marker), and improved HbA1c. [3]
- Immune function Glutathione plays a role in T-cell proliferation and natural killer cell activity; a four-week randomized trial of oral liposomal glutathione found elevations in both blood glutathione stores and markers of immune function compared to placebo. [4]
- Skin pigmentation Glutathione inhibits tyrosinase, the enzyme central to melanin synthesis; small randomized controlled trials have examined oral glutathione supplementation for skin lightening, with the most consistent data supporting topical or mucosal delivery over standard oral dosing. [5]
- Mitochondrial function and muscle GlyNAC (glycine + N-acetylcysteine) supplementation — a precursor strategy designed to raise intracellular glutathione — has been studied in older adults with findings of improved mitochondrial fuel oxidation, reduced muscle wasting markers, and better physical performance; researchers view glutathione deficiency as a potential upstream target in age-related muscle loss. [1]
Glutathione has a more developed clinical evidence base than most compounds in the research peptide space. There are multiple randomized controlled trials in humans across metabolic, immune, and aging endpoints. The GlyNAC research in particular — conducted at Baylor College of Medicine and now spanning both a pilot trial and a full placebo-controlled RCT — is among the more methodologically rigorous work in the aging supplement literature. The T2D oral glutathione trial enrolled 250 diabetic individuals in a six-month study, a size and duration unusual in this space. [1] [2] [3]
The central complication in this evidence base is bioavailability. Standard oral glutathione is partially broken down in the gastrointestinal tract before absorption — the tripeptide does not survive digestion intact in substantial quantities. Liposomal encapsulation addresses this by protecting the compound during transit; the Sinha et al. trial found measurably higher blood glutathione levels from the liposomal form compared to baseline. [4] Precursor approaches, particularly GlyNAC, sidestep the bioavailability problem entirely by supplying the amino acid building blocks the body uses to synthesize glutathione intracellularly. For researchers interested in raising intracellular glutathione, GlyNAC has emerged as a well-studied route that does not depend on intestinal absorption of the intact molecule.
| Parameter | Detail |
|---|---|
| Common supplement forms | Standard oral capsule/tablet, liposomal oral, sublingual/buccal, IV infusion; precursor supplements (NAC, GlyNAC) |
| Supplied as | Reduced glutathione (GSH) — the active form; oxidized glutathione (GSSG) is inactive |
| Storage | Cool, dry, away from direct light; some liposomal formulations require refrigeration |
| Stability | Sensitive to heat, moisture, and oxidation; reduced form degrades faster than precursors; check COA and expiration |
| Administration studied | Oral (250–1,000 mg/day in most trials); liposomal oral; IV (clinical / grey market); buccal/sublingual patches in newer studies |
- [1] Sekhar RV, et al. Glycine and N-Acetylcysteine (GlyNAC) Supplementation in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Insulin Resistance, Endothelial Dysfunction, Genotoxicity, Muscle Strength, and Cognition: Results of a Pilot Clinical Trial. Clin Transl Med. 2021;11(3):e372. PubMed ↗
- [2] Sekhar RV, et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. J Nutr. 2022;152(12):2781-2798. PubMed ↗
- [3] Kalamkar S, et al. Randomized Clinical Trial of How Long-Term Glutathione Supplementation Offers Protection from Oxidative Damage and Improves HbA1c in Elderly Type 2 Diabetic Patients. Antioxidants. 2022;11(5):1026. PMC ↗
- [4] Sinha R, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72(1):105-111. DOI: 10.1038/ejcn.2017.132.
- [5] Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97-102. PubMed ↗